Evidence map›Paper›PMID 36278447›Full record

ReviewCurrent cancer drug targets2023

Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives.

Yan Zhang, Yafei Li, Qiuxia Fu, Zhiqiang Han, Daijie Wang, Shafiu A Umar Shinge, Tobias Achu Muluh, Xiaohong Lu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yan ZhangDepartment of Oncology, The People's Hospital of Luzhou, 646000 Luzhou, Sichuan, P.R. China.
Yafei LiDepartment of Oncology, The People's Hospital of Luzhou, 646000 Luzhou, Sichuan, P.R. China.
Qiuxia FuDepartment of Oncology, The People's Hospital of Luzhou, 646000 Luzhou, Sichuan, P.R. China.
Zhiqiang HanDepartment of Oncology, The People's Hospital of Luzhou, 646000 Luzhou, Sichuan, P.R. China.
Daijie WangDepartment of Oncology, The People's Hospital of Luzhou, 646000 Luzhou, Sichuan, P.R. China.
Shafiu A Umar ShingeDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Sichuan, P.R. China.
Tobias Achu MuluhDepartment of Cardiovascular Surgery, The Affiliated Hospital of Southwest Medical University, Sichuan, P.R. China.
Xiaohong LuDepartment of Oncology, The People's Hospital of Luzhou, 646000 Luzhou, Sichuan, P.R. China.
First Affiliated Hospital of Sichuan Medical University · CNAffiliated Hospital of Southwest Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The previous year's worldview for cancer treatment has advanced from general to more precise therapeutic approaches. Chemotherapies were first distinguished as the most reliable and brief therapy with promising outcomes in cancer patients. However, patients could also suffer from severe toxicities resulting from chemotherapeutic drug usage. An improved comprehension of cancer pathogenesis has led to new treatment choices, including tumor-targeted therapy and immunotherapy. Subsequently, cancer immunotherapy and targeted therapy give more hope to patients since their combination has tremendous therapeutic efficacy. The immune system responses are also initiated and modulated by targeted therapies and cytotoxic agents, which create the principal basis that when targeted therapies are combined with immunotherapy, the clinical outcomes are of excellent efficacy, as presented in this review. This review focuses on how immunotherapy and targeted therapy are applicable in cancer management and treatment. Also, it depicts promising therapeutic results with more extensive immunotherapy applications with targeted therapy. Further elaborate that immune system responses are also initiated and modulated by targeted therapies and cytotoxic agents, which create the principal basis that this combination therapy with immunotherapy can be of great outcome clinically.

Indexed as

ImmunotherapyNeoplasmsCombined Modality TherapyCytotoxinsHumansCytotoxinsantibodiesdendritic-cellimmunityImmunotherapytargeted-therapiesT-cell

Identifiers

PMID36278447
OpenAlexW4307052074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.